Мы используем файлы cookie.
Продолжая использовать сайт, вы даете свое согласие на работу с этими файлами.
Продолжая использовать сайт, вы даете свое согласие на работу с этими файлами.
TFM-4AS-1
Подписчиков: 0, рейтинг: 0
Clinical data | |
---|---|
Other names | N-[2-(Trifluoromethyl)phenyl]-3-oxo-4-aza-4-methyl-5α-androst-1-en-17α-carboxamide |
Identifiers | |
| |
CAS Number | |
PubChem CID | |
ChemSpider | |
Chemical and physical data | |
Formula | C27H33F3N2O2 |
Molar mass | 474.568 g·mol−1 |
3D model (JSmol) | |
| |
|
TFM-4AS-1 is a dual selective androgen receptor modulator (SARM) and 5α-reductase inhibitor. It is a potent and selective partial agonist (Emax = 55%) of the androgen receptor (IC50 = 30 nM) and inhibitor of 5α-reductase types I and II (IC50 = 2 and 3 nM, respectively). TFM-4AS-1 shows tissue-selective androgenic effects; it promotes the accumulation of bone and muscle mass and has reduced effects in reproductive tissues and sebaceous glands. In addition, it does not promote growth of the prostate gland and it antagonizes the actions of dihydrotestosterone (DHT) in the seminal vesicles. Structurally, TFM-4AS-1 is a 4-azasteroid.